Trial · NCT03514420
Results by group63
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 63
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides Levels at End of the Treatment (Week 27) | AKCEA-ANGPTL3-LRx 20 mg | -59.9 | Standard Deviation 26.29 | percent change | |
| Change From Baseline in Area Under the Curve (AUC) of Plasma Glucose as Assessed by Mixed Meal Test (MMT) at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | -9815.0 | Standard Deviation 4071.43 | mg/dL*min | |
| Change From Baseline in AUC of Serum Insulin as Assessed by MMT at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | 3262.0 | Standard Deviation 3775.09 | milli international units per liter*min | |
| Change From Baseline in AUC of Serum C-peptide as Assessed by MMT at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | -192.3 | Standard Deviation 257.10 | ng/mL*min | |
| Change From Baseline in AUC of Free Fatty Acid (FFA) as Assessed by MMT at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | -60.0 | Standard Deviation 42.52 | mEq/L*min | |
| Change From Baseline in AUC of Serum Ghrelin as Assessed by MMT at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | 8479.5 | Standard Deviation 7241.20 | pg/mL*min | |
| Change From Baseline in AUC of Incretin Hormone (Gastric Inhibitory Polypeptide [GIP]) as Assessed by MMT at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | -1694.7 | Standard Deviation 11752.50 | pg/mL*min | |
| Change From Baseline in AUC of Incretin Hormone (Glucagon-like Peptide -1 [GLP-1]) as Assessed by MMT at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | 1677.3 | Standard Deviation 11301.79 | pmol/L*min | |
| Change From Baseline in AUC of Peptide Tyrosine Tyrosine (PYY) as Assessed by MMT at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | 6549.0 | Standard Deviation 10632.50 | pg/mL*min | |
| Change From Baseline in HDL-C at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | 2.1 | Standard Deviation 6.88 | mg/dL | |
| Change From Baseline in LDL-C at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | 24.0 | Standard Deviation NA | mg/dL | |
| Change From Baseline in Total Cholesterol (TC) at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | -42.3 | Standard Deviation 32.29 | mg/dL | |
| Change From Baseline in VLDL-C at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | -32.0 | Standard Deviation NA | mg/dL | |
| Change From Baseline in Non-HDL-C at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | -44.4 | Standard Deviation 34.27 | mg/dL | |
| Change From Baseline in ApoB at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | 1.25 | Standard Deviation 25.265 | mg/dL | |
| Change From Baseline in ApoB-48 at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | -3.601 | Standard Deviation 1.3284 | mg/dL | |
| Change From Baseline in Apolipoprotein B 100 (ApoB-100) at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | 4.433 | Standard Deviation 24.6001 | mg/dL | |
| Change From Baseline in ApoA-1 at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | -20.8 | Standard Deviation 22.92 | mg/dL | |
| Change From Baseline in ApoC-III at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | -13.555 | Standard Deviation 9.1220 | mg/dL | |
| Change From Baseline in ApoC-III: LDL at End of the Treatment | AKCEA-ANGPTL3-LRx 20 mg | -2.110 | Standard Deviation NA | mg/dL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03514420/results